Wenger Vieli advises NLS Pharmaceutics on a private placement
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m.
NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders. NLS intends to use the net proceeds from the offering to fund the ongoing development of its lead product, Quilience®for the treatment of narcolepsy, to support business development and licensing activities, and for general corporate purposes.
The Wenger Vieli team was led by partner Pascal Honold (m&a /vc/pe, pictured) and included Kevin Vangehr (associate, m&a / vc/pe), Alessa Waibel (associate, financial services) and Andrea Christen (associate, m&a / vc/pe).